NHS England has proposed a phased rollout of tirzepatide, a promising weight-loss drug, to benefit patients most likely to achieve significant clinical outcomes.
Tirzepatide, branded as Mounjaro and produced by Eli Lilly And Co (NYSE:LLY), has shown remarkable results in clinical trials. It offers greater weight loss than existing therapies like Novo Nordisk A/S’ (NYSE:NVO) and Ozempic (semaglutide).
In the SURMOUNT-4 trial, patients lost an average of 20.9% of their body weight in 36 weeks.
Also Read: Popular Weight Loss Drugs Like Ozempic Show Gap Between Clinical Trial Promises And Real-World Use, Study Reveals.
The plan, currently under consultation, aims ...
